Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors
Phase II Clinical Trial
A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-PanTumor02) (DS7300-203)
Indication: Colon Cancer, Endometrial Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer
